Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib
Julie A. Schneider, Ann Schalenbourg, Jean Dudler, Yan Guex‐Crosier
Abstract
Janus activated kinases (JAKs) are a family of intracellular tyrosine kinases that function as intracellular mediators of multiple cytokines and growth factors involved in the pathogenesis of inflammation and immune-mediated diseases. Many JAK inhibitors (JAKinibs) have been developed over recent years and they have emerged as a new therapeutic class for immune-mediated inflammatory diseases. Tofacitinib (Xeljanz, an anti JAK1-JAK3 agent) and baricitinib (Omlumiant, an anti JAK1-JAK2 agent) are first-generation JAKinibs. Upadacitinib (Rinvoq) is a specific, newer Janus kinase (JAK-1) inhibitor recently approved for the treatment of inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and psoriatic arthritis [1], [2], [3], [4]. However, few data are available on the use of these recent therapies in the management of ocular inflammation.